FI113964B - Pyrrolitsiini- ja pyrrolo [2,1-b] tiatsolijohdannaiset, niiden välituotteet ja käyttö farmasiassa - Google Patents

Pyrrolitsiini- ja pyrrolo [2,1-b] tiatsolijohdannaiset, niiden välituotteet ja käyttö farmasiassa

Info

Publication number
FI113964B
FI113964B FI964771A FI964771A FI113964B FI 113964 B FI113964 B FI 113964B FI 964771 A FI964771 A FI 964771A FI 964771 A FI964771 A FI 964771A FI 113964 B FI113964 B FI 113964B
Authority
FI
Finland
Prior art keywords
pct
pyrrolizine
pyrrolo
intermediates
pharmaceutical uses
Prior art date
Application number
FI964771A
Other languages
English (en)
Swedish (sv)
Other versions
FI964771A0 (fi
FI964771A (fi
Inventor
Stefan Laufer
Hans Guenther Striegel
Gerd Dannhardt
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of FI964771A0 publication Critical patent/FI964771A0/fi
Publication of FI964771A publication Critical patent/FI964771A/fi
Application granted granted Critical
Publication of FI113964B publication Critical patent/FI113964B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
FI964771A 1994-06-01 1996-11-29 Pyrrolitsiini- ja pyrrolo [2,1-b] tiatsolijohdannaiset, niiden välituotteet ja käyttö farmasiassa FI113964B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4419246A DE4419246A1 (de) 1994-06-01 1994-06-01 Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
PCT/EP1995/002077 WO1995032970A1 (de) 1994-06-01 1995-05-31 [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE

Publications (3)

Publication Number Publication Date
FI964771A0 FI964771A0 (fi) 1996-11-29
FI964771A FI964771A (fi) 1997-01-27
FI113964B true FI113964B (fi) 2004-07-15

Family

ID=6519584

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964771A FI113964B (fi) 1994-06-01 1996-11-29 Pyrrolitsiini- ja pyrrolo [2,1-b] tiatsolijohdannaiset, niiden välituotteet ja käyttö farmasiassa

Country Status (14)

Country Link
US (1) US5958943A (fi)
EP (1) EP0763036B1 (fi)
JP (1) JP3671302B2 (fi)
KR (1) KR100378883B1 (fi)
AT (1) ATE223917T1 (fi)
AU (1) AU2672895A (fi)
CA (1) CA2191747C (fi)
DE (2) DE4419246A1 (fi)
DK (1) DK0763036T3 (fi)
ES (1) ES2182903T3 (fi)
FI (1) FI113964B (fi)
NO (1) NO310291B1 (fi)
PT (1) PT763036E (fi)
WO (1) WO1995032970A1 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005080A (es) * 1999-11-23 2002-12-09 Merckle Gmbh Oxo e hidroxi derivados antiinflamatorios de pirrolizinas y su uso en farmacia.
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
RS50374B (sr) 2000-01-28 2009-11-10 Merckle Gmbh., Postupak za dobijanje 6-(4-hlorfenil)-2,2-dimetil-7-fenil -2,3-dihidro-1h-pirolizin-5-il-sirćetne kiseline
DE10004157A1 (de) * 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie
DE10141285A1 (de) 2001-08-23 2003-03-27 Merckle Gmbh Verfahren zur Herstellung von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phnyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
UA77812C2 (en) * 2002-05-17 2007-01-15 Merckle Gmbh Anelated pyrrol substances as proton pump inhibitors for treating gastric ulcer
JP2006511479A (ja) * 2002-09-27 2006-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３，４−二置換ピロールおよび炎症性疾患の治療におけるこれらの使用
MXPA05013364A (es) * 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形
SG158168A1 (en) * 2004-12-23 2010-01-29 Arena Pharm Inc 5ht2c receptor modulator compositions and methods of use
DE102005012971A1 (de) * 2005-03-21 2006-09-28 Merckle Gmbh Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure
WO2007120517A2 (en) * 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
JP5404414B2 (ja) * 2006-12-05 2014-01-29 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法
WO2009111004A1 (en) * 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
MX2013002421A (es) 2010-09-01 2013-05-17 Arena Pharm Inc Sales no hidroscopicas de agonistas de 5-ht2c.
WO2012030939A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1461592A (en) * 1973-04-25 1977-01-13 Agfa Gevaert Specially sensitized direct positive silver halide emulsions
US3920672A (en) * 1974-08-22 1975-11-18 Syntex Inc Thiacycl (2.2.2.)azine carboxylic acids
US4536512A (en) * 1982-10-08 1985-08-20 Merck & Co., Inc. 5-(2,3-Dihydro-1H-pyrrolizin-5-oyl)-2,3-dihydro-1H-pyrrolizine-1-alkanoic or carboxylic acids and use thereof as anti-inflammatory and analgesic agents
FR2539417A1 (fr) * 1983-01-13 1984-07-20 Rhone Poulenc Sante Nouveaux pyrrolo-1, 2 heterocycles, leur preparation et les medicaments qui les contiennent
GR81681B (fi) * 1983-01-13 1984-12-12 Rhone Poulenc Sante
FR2557111B1 (fr) * 1983-12-21 1986-04-11 Rhone Poulenc Sante Nouveaux derives ortho-condenses du pyrrole, leur preparation et les medicaments qui les contiennent
US5260451A (en) * 1989-05-11 1993-11-09 Merckle Gmbh Substituted pyrrole compounds and use thereof in pharmaceutical compositions
DE3915450A1 (de) * 1989-05-11 1990-11-15 Gerd Prof Dr Dannhardt Substituierte pyrrolverbindungen und deren anwendung in der pharmazie
JPH05289267A (ja) * 1992-04-07 1993-11-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents

Also Published As

Publication number Publication date
US5958943A (en) 1999-09-28
CA2191747C (en) 2007-01-23
KR100378883B1 (ko) 2003-08-02
NO965093D0 (no) 1996-11-29
DK0763036T3 (da) 2002-12-02
NO310291B1 (no) 2001-06-18
FI964771A0 (fi) 1996-11-29
CA2191747A1 (en) 1995-12-07
EP0763036A1 (de) 1997-03-19
WO1995032970A1 (de) 1995-12-07
ES2182903T3 (es) 2003-03-16
JPH10506368A (ja) 1998-06-23
AU2672895A (en) 1995-12-21
DE59510370D1 (de) 2002-10-17
DE4419246A1 (de) 1995-12-07
ATE223917T1 (de) 2002-09-15
NO965093L (no) 1996-11-29
FI964771A (fi) 1997-01-27
JP3671302B2 (ja) 2005-07-13
EP0763036B1 (de) 2002-09-11
PT763036E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
FI113964B (fi) Pyrrolitsiini- ja pyrrolo [2,1-b] tiatsolijohdannaiset, niiden välituotteet ja käyttö farmasiassa
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
BR9609617B1 (pt) derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
FI954718A (fi) Heterosykliset johdannaiset iskeemian ja vastaavien sairauksien hoitamiseksi
FI964772A0 (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
MX9707453A (es) Derivados de quinazolina.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BG103417A (en) Condensed pyrimidine bicyclic derivatives
DE122010000050I2 (de) Sublinguales oder bukkales arzneimittel.
BG101118A (en) Therapeutical compounds
ATE384068T1 (de) Thiazolo(4,5-d)pyrimidinverbindungen zur behandlung von rheumathoider arthritis
FR2721608B1 (fr) Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
CA2191746A1 (en) [a]-annelated pyrrole derivatives and pharmaceutical use thereof
AU1929688A (en) Leukotriene antagonists, processes for the preparation thereof, the use thereof for the treatment of diseases, and precursors
IT1261994B (it) Derivati guanidinici ad uso terapeutico.
CO4290357A1 (es) Derivados de la cefalosporina, preparaciones farmaceuticas que las contienen y procedimiento para su preparacion y em- pleo.
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate
ES2068739A1 (es) Inhibidores retrovirables de proteasas.